Literature DB >> 9422084

Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996.

M R Price1, P D Rye, E Petrakou, A Murray, K Brady, S Imai, S Haga, Y Kiyozuka, D Schol, M F Meulenbroek, F G Snijdewint, S von Mensdorff-Pouilly, R A Verstraeten, P Kenemans, A Blockzjil, K Nilsson, O Nilsson, M Reddish, M R Suresh, R R Koganty, S Fortier, L Baronic, A Berg, M B Longenecker, J Hilgers.   

Abstract

Sixteen research groups participated in the ISOBM TD-4 Workshop in which the reactivity and specificity of 56 monoclonal antibodies against the MUC1 mucin was investigated using a diverse panel of target antigens and MUC1 mucin-related synthetic peptides and glycopeptides. The majority of antibodies (34/56) defined epitopes located within the 20-amino acid tandem repeat sequence of the MUC1 mucin protein core. Of the remaining 22 antibodies, there was evidence for the involvement of carbohydrate residues in the epitopes for 16 antibodies. There was no obvious relationship between the type of immunogen and the specificity of each antibody. Synthetic peptides and glycopeptides were analyzed for their reactivity with each antibody either by assay of direct binding (e.g. by ELISA or BiaCore) or by determining the capacity of synthetic ligands to inhibit antibody binding interactions. There was good concordance between the research groups in identifying antibodies reactive with peptide epitopes within the MUC1 protein core. Epitope mapping tests were performed using the Pepscan analysis for antibody reactivity against overlapping synthetic peptides, and results were largely consistent between research groups. The dominant feature of epitopes within the MUC1 protein core was the presence, in full or part, of the hydrophilic sequence of PDTRAPAP. Carbohydrate epitopes were less easily characterized and the most useful reagents in this respect were defined oligosaccharides, rather than purified mucin preparations enriched in particular carbohydrate moieties. It was evident that carbohydrate residues were involved in many epitopes, by regulating epitope accessibility or masking determinants, or by stabilizing preferred conformations of peptide epitopes within the MUC1 protein core. Overall, the studies, highlight concordance between groups rather than exposing inconsistencies which gives added confidence to the results of analyses of the specificity of antimucin monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9422084     DOI: 10.1159/000056500

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  55 in total

1.  A high-throughput O-glycopeptide discovery platform for seromic profiling.

Authors:  Ola Blixt; Emiliano Cló; Aaron S Nudelman; Kasper Kildegaard Sørensen; Thomas Clausen; Hans H Wandall; Philip O Livingston; Henrik Clausen; Knud J Jensen
Journal:  J Proteome Res       Date:  2010-10-01       Impact factor: 4.466

2.  Hypervariability of the membrane-associated mucin and cancer marker MUC1.

Authors:  Joanna C Fowler; Ana S Teixeira; Lynne E Vinall; Dallas M Swallow
Journal:  Hum Genet       Date:  2003-08-27       Impact factor: 4.132

3.  Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.

Authors:  Kirstine Lavrsen; Caroline B Madsen; Morten G Rasch; Anders Woetmann; Niels Ødum; Ulla Mandel; Henrik Clausen; Anders E Pedersen; Hans H Wandall
Journal:  Glycoconj J       Date:  2012-08-10       Impact factor: 2.916

4.  Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer.

Authors:  Vandana G Abramson; Ingrid A Mayer
Journal:  Curr Treat Options Oncol       Date:  2011-12

Review 5.  MUC1 and MUC4: switching the emphasis from large to small.

Authors:  Huguette Albrecht; Kermit L Carraway
Journal:  Cancer Biother Radiopharm       Date:  2011-06       Impact factor: 3.099

Review 6.  Glycoprotein disease markers and single protein-omics.

Authors:  Kevin Chandler; Radoslav Goldman
Journal:  Mol Cell Proteomics       Date:  2013-02-11       Impact factor: 5.911

Review 7.  Mucin-based targeted pancreatic cancer therapy.

Authors:  Maria P Torres; Subhankar Chakraborty; Joshua Souchek; Surinder K Batra
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 8.  Imaging in targeted delivery of therapy to cancer.

Authors:  Gairin Dancey; Richard H Begent; Tim Meyer
Journal:  Target Oncol       Date:  2009-10-08       Impact factor: 4.493

9.  MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy.

Authors:  Sara K Lindén; Yong H Sheng; Alison L Every; Kim M Miles; Emma C Skoog; Timothy H J Florin; Philip Sutton; Michael A McGuckin
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823

10.  Phototoxic aptamers selectively enter and kill epithelial cancer cells.

Authors:  Cátia S M Ferreira; Melissa C Cheung; Sotiris Missailidis; Stuart Bisland; Jean Gariépy
Journal:  Nucleic Acids Res       Date:  2008-12-22       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.